PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(11): 1954-1962
DOI: 10.1055/a-1869-7853
Trial Protocol Design Paper

Point-of-Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study

Annahita Sedghi   *
1   Department of Neurology, Dresden Neurovascular Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Lars Heubner    *
2   Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus, Dresden, Germany
,
Anna Klimova
3   National Center for Tumor Diseases Partner Site Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
4   Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
,
Oliver Tiebel
5   Institute of Clinical Chemistry, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Jörg Pietsch
6   Institute of Forensic Medicine, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
,
Martin Mirus
2   Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus, Dresden, Germany
,
Kristian Barlinn
1   Department of Neurology, Dresden Neurovascular Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Tabea Minx
1   Department of Neurology, Dresden Neurovascular Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Jan Beyer-Westendorf
7   Department of Internal Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Volker Puetz
1   Department of Neurology, Dresden Neurovascular Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Peter Spieth   **
2   Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus, Dresden, Germany
,
Timo Siepmann   **
1   Department of Neurology, Dresden Neurovascular Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
› Institutsangaben Funding The study was funded by the Faculty of Medicine Carl Gustav Carus of the Technische Universität Dresden as well as the University Hospital Carl Gustav Carus Dresden.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Background Treatment of ischemic stroke with recombinant tissue plasminogen activator for intravenous thrombolysis (IVT) must be delivered within a narrow time window after symptom onset. This effective hyperacute treatment can be administered after ruling out active anticoagulation with direct oral anticoagulants (DOACs). Whenever this is impractical, e.g., due to aphasia, plasmatic DOAC levels are measured with a consequent delay in the IVT decision-making process ranging from 30 to 60 minutes of time. This study will test the hypothesis that hyperacute point-of-care assessment of clotting time in the patient's whole blood has sufficient diagnostic accuracy to determine immediately whether stroke patients are pretreated with DOAC.

Methods and Design This will be a prospective single-center diagnostic accuracy study in 1,850 consecutive acute ischemic stroke patients at a tertiary stroke center in Saxony, Germany. Presence of active anticoagulation with DOAC will be determined by point-of-care quantification of clotting time via whole blood viscoelastic testing (ClotPro) using Russell venom viper and ecarin assay compared with high-performance liquid chromatography-tandem mass spectrometry as the reference standard.

Discussion Viscoelastic point-of-care assessment of clotting time in whole blood might improve swift delivery of time-sensitive hyperacute treatment with IVT in stroke patients.

Keywords

stroke prevention - thrombolysis - oral anticoagulants - inhibitors

Author Contributions

A.S., L.H., O.T., J.P., J.B.-W., V.P., P.S., and T.S. conceptualized the study. A.K. and A.S. were involved in sample size calculation and statistical analysis. A.S. wrote the first draft of the manuscript. O.T., J.P., J.B.-W., P.S., and T.S. provided resources. L.H., A.K., O.T., J.P., M.M., K.B., T.M., J.B.-W., V.P., P.S., and T.S. reviewed the manuscript for intellectual content. All authors agreed to be accountable for the content of the work.


Ethical Approval

The study has been conducted according to the current revised form of the Helsinki Declaration (2000, Edinburgh, Scotland). The study protocol has been approved by the institutional review board (IRB) of Technische Universität Dresden (Study reference: BO-EK 515102021). This study is registered with the German Clinical Trials Register DRKS00028597.


Informed Consent

No written informed consent is necessary as all screening or specific quantitative laboratory assays are performed as part of clinical routine. Thereby, a prospective database is generated. The index test as well as the reference test is intended to measure the same parameters but with a different method and diagnostic accuracy.


Confidentiality

Physical copies of informed consent forms will be stored onsite and converted to electronic files. Case report forms will not contain patients' initials or birth dates but only a study number. All the data will be treated confidentially and only trial investigators will be authorized to access to the hard drives.


Access to Data

The final trial dataset will be available to all investigators of the study.


Dissemination Policy

This protocol paper was written in accordance with the SPIRIT 2013 Statement on the composition of protocol papers (https://www.spirit-statement.org/protocol-version/). The complete dataset and statistical code will be available upon reasonable request.


* Shared first authorship.


** Shared last authorship.




Publikationsverlauf

Eingereicht: 02. April 2022

Angenommen: 27. Mai 2022

Accepted Manuscript online:
07. Juni 2022

Artikel online veröffentlicht:
17. Oktober 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 (24) 1581-1587
    CrossrefPubMedGoogle Scholar
  • 2 Hacke W, Kaste M, Fieschi C. et al; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136): 1245-1251
    CrossrefPubMedGoogle Scholar
  • 3 Hacke W, Kaste M, Bluhmki E. et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 (13) 1317-1329
    CrossrefPubMedGoogle Scholar
  • 4 Ma H, Campbell BCV, Parsons MW. et al; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019; 380 (19) 1795-1803
    CrossrefPubMedGoogle Scholar
  • 5 Thomalla G, Simonsen CZ, Boutitie F. et al; WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018; 379 (07) 611-622
    CrossrefPubMedGoogle Scholar
  • 6 Saver JL, Smith EE, Fonarow GC. et al; GWTG-Stroke Steering Committee and Investigators. The “golden hour” and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke 2010; 41 (07) 1431-1439
    CrossrefPubMedGoogle Scholar
  • 7 Man S, Xian Y, Holmes DN. et al. Association between thrombolytic door-to-needle time and 1-year mortality and readmission in patients with acute ischemic stroke. JAMA 2020; 323 (21) 2170-2184
    CrossrefPubMedGoogle Scholar
  • 8 Kamal N, Smith EE, Jeerakathil T, Hill MD. Thrombolysis: improving door-to-needle times for ischemic stroke treatment - a narrative review. Int J Stroke 2018; 13 (03) 268-276
    CrossrefPubMedGoogle Scholar
  • 9 Whaley M, Caputo L, Kozlowski M, Fanale C, Wagner J, Bar-Or D. A door-to-needle time under 30 minutes can be achieved and can improve functional outcomes (S21.004). Neurology 2015;84(14, Supplement)
    PubMedGoogle Scholar
  • 10 Ringleb P, Köhrmann M, Jansen O. et al. Akuttherapie des ischämischen Schlaganfalls, S2e-Leitlinie, 2021, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Accessed July 18, 2022 at: www.dgn.org/leitlinien
    Google Scholar
  • 11 Fonarow GC, Zhao X, Smith EE. et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014; 311 (16) 1632-1640
    CrossrefPubMedGoogle Scholar
  • 12 Powers WJ, Rabinstein AA, Ackerson T. et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019; 50 (12) e344-e418
    CrossrefPubMedGoogle Scholar
  • 13 Berge E, Whiteley W, Audebert H. et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021; 6 (01) I-LXII
    CrossrefPubMedGoogle Scholar
  • 14 Piccini Sr JP, Fonarow GC. Preventing stroke in patients with atrial fibrillation-a steep climb away from achieving peak performance. JAMA Cardiol 2016; 1 (01) 63-64
    CrossrefPubMedGoogle Scholar
  • 15 López-López JA, Sterne JAC, Thom HHZ. et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
    CrossrefPubMedGoogle Scholar
  • 16 Tsivgoulis G, Safouris A. Intravenous thrombolysis in acute ischemic stroke patients pretreated with non-vitamin K antagonist oral anticoagulants: an editorial review. Stroke 2017; 48 (07) 2031-2033
    CrossrefPubMedGoogle Scholar
  • 17 Auer E, Frey S, Kaesmacher J. et al. Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists. J Neurol 2019; 266 (09) 2263-2272
    CrossrefPubMedGoogle Scholar
  • 18 Sakamoto Y, Okubo S, Nito C. et al. The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation. Eur J Neurol 2017; 24 (11) 1399-1406
    CrossrefPubMedGoogle Scholar
  • 19 Meinel TR, Branca M, De Marchis GM. et al; Investigators of the Swiss Stroke Registry. Prior anticoagulation in patients with ischemic stroke and atrial fibrillation. Ann Neurol 2021; 89 (01) 42-53
    CrossrefPubMedGoogle Scholar
  • 20 Seiffge DJ, De Marchis GM, Koga M. et al; RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen, and Verona registry collaborators. Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol 2020; 87 (05) 677-687
    CrossrefPubMedGoogle Scholar
  • 21 Winther-Larsen A, Hvas AM. Clinical impact of direct oral anticoagulant measuring in a real-life setting. Thromb Res 2019; 175: 40-45
    CrossrefPubMedGoogle Scholar
  • 22 Siller T, Chandratheva A, Bücke P, Werring DJ, Seiffge D. Acute stroke treatment in an anticoagulated patient: when is thrombolysis an option?. Curr Treat Options Neurol 2021; 23 (12) 41
    CrossrefPubMedGoogle Scholar
  • 23 Dunois C. Laboratory monitoring of direct oral anticoagulants (DOACs). Biomedicines 2021; 9 (05) 445
    CrossrefPubMedGoogle Scholar
  • 24 Shahjouei S, Tsivgoulis G, Goyal N. et al. Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: a systematic review and meta-analysis. Stroke 2020; 51 (02) 533-541
    CrossrefPubMedGoogle Scholar
  • 25 Seiffge DJ, Poli S, Meinel TR, Wu T, Wilson D, Purrucker JC. Intravenous thrombolysis in patients taking direct oral anticoagulants (ESO IVT guidelines comment). Eur Stroke J 2021; 6 (04) 445-446
    CrossrefPubMedGoogle Scholar
  • 26 Touzé E, Gruel Y, Gouin-Thibault I. et al. Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. Eur J Neurol 2018; 25 (05) 747-e52
    CrossrefPubMedGoogle Scholar
  • 27 Ebner M, Birschmann I, Peter A. et al. Limitations of specific coagulation tests for direct oral anticoagulants: a critical analysis. J Am Heart Assoc 2018; 7 (19) e009807
    CrossrefPubMedGoogle Scholar
  • 28 Härtig F, Birschmann I, Peter A. et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban. Neurol Res Pract 2021; 3 (01) 9
    CrossrefPubMedGoogle Scholar
  • 29 Drouet L, Bal Dit Sollier C, Steiner T, Purrucker J. Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used?. Int J Stroke 2016; 11 (07) 748-758
    CrossrefPubMedGoogle Scholar
  • 30 Harenberg J, Beyer-Westendorf J, Crowther M. et al; Working Group Members. Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine-a multicenter trial. Thromb Haemost 2020; 120 (01) 132-140
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 31 Douxfils J, Ageno W, Samama CM. et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16 (02) 209-219
    CrossrefPubMedGoogle Scholar
  • 32 Zepeski AE, Faine BA, Merrill AE, Sutamtewagul G, Bhagavathi S. Utilization of anti-factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department. Am J Health Syst Pharm 2022; 79 (01) e20-e26
    CrossrefPubMedGoogle Scholar
  • 33 Seiffge DJ, Kägi G, Michel P. et al; Novel Oral Anticoagulants in Stroke Patients study group. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. Ann Neurol 2018; 83 (03) 451-459
    CrossrefPubMedGoogle Scholar
  • 34 Sahli SD, Rössler J, Tscholl DW, Studt JD, Spahn DR, Kaserer A. Point-of-care diagnostics in coagulation management. Sensors (Basel) 2020; 20 (15) E4254
    CrossrefPubMedGoogle Scholar
  • 35 Härtig F, Birschmann I, Peter A. et al. Point-of-care testing of coagulation in patients treated with edoxaban. J Thromb Thrombolysis 2020; 50 (03) 632-639
    CrossrefPubMedGoogle Scholar
  • 36 Calatzis HL, Hipp Q, Spannagl M. ClotPro - a new generation viscoelastic whole blood coagulation analyzer. Hamostaseologie 2018; P013
    PubMedGoogle Scholar
  • 37 Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89 (02) 228-232
    CrossrefPubMedGoogle Scholar
  • 38 Rossaint R, Bouillon B, Cerny V. et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016; 20: 100
    CrossrefPubMedGoogle Scholar
  • 39 American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology 2015; 122 (02) 241-275
    CrossrefPubMedGoogle Scholar
  • 40 Schmidt DE, Holmström M, Majeed A, Näslin D, Wallén H, Ågren A. Detection of elevated INR by thromboelastometry and thromboelastography in warfarin treated patients and healthy controls. Thromb Res 2015; 135 (05) 1007-1011
    CrossrefPubMedGoogle Scholar
  • 41 Henskens YMC, Gulpen AJW, van Oerle R. et al. Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. Thromb J 2018; 16: 3
    CrossrefPubMedGoogle Scholar
  • 42 Dias JD, Lopez-Espina CG, Ippolito J. et al. Rapid point-of-care detection and classification of direct-acting oral anticoagulants with the TEG 6s: implications for trauma and acute care surgery. J Trauma Acute Care Surg 2019; 87 (02) 364-370
    CrossrefPubMedGoogle Scholar
  • 43 Pailleret C, Jourdi G, Siguret V. et al. Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: A diagnostic test study. Eur J Anaesthesiol 2019; 36 (06) 449-456
    CrossrefPubMedGoogle Scholar
  • 44 Groene P, Wagner D, Kammerer T. et al. Viscoelastometry for detecting oral anticoagulants. Thromb J 2021; 19 (01) 18
    CrossrefPubMedGoogle Scholar
  • 45 Schäfer ST, Otto AC, Acevedo AC. et al. Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms. Thromb J 2021; 19 (01) 63
    CrossrefPubMedGoogle Scholar
  • 46 Margetić S, Ćelap I, Huzjan AL. et al. DOAC dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in circulation. Thromb Haemost 2022; 122 (09) 1542-1548
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 47 Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008; 130 (03) 446-454
    CrossrefPubMedGoogle Scholar
  • 48 Oberladstätter D, Voelckel W, Schlimp C. et al. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia 2021; 76 (03) 373-380
    CrossrefPubMedGoogle Scholar
  • 49 Studt JD, Alberio L, Angelillo-Scherrer A. et al. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. J Thromb Haemost 2017; 15 (08) 1576-1583
    CrossrefPubMedGoogle Scholar
  • 50 Mavri A, Vene N, Božič-Mijovski M. et al. Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep 2021; 11 (01) 13908
    CrossrefPubMedGoogle Scholar
  • 51 Tiebel OR, Mirtschink P. Haematology, including haemostasis. Clin Chem Lab Med 2021; 59 (s1): s485-s540
    CrossrefPubMedGoogle Scholar
  • 52 Bruckner L, Beyer-Westendorf J, Tiebel O, Pietsch J. Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS. J Thromb Thrombolysis 2021; 53 (04) 777-787
    CrossrefPubMedGoogle Scholar
  • 53 Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med 1996; 3 (09) 895-900
    CrossrefPubMedGoogle Scholar
  • 54 Šimundić AM. Measures of diagnostic accuracy: basic definitions. EJIFCC 2009; 19 (04) 203-211
    PubMedGoogle Scholar
  • 55 Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost 2010; 8 (04) 621-626
    CrossrefPubMedGoogle Scholar